IL314054A - Uses of a somatostatin modulator for the treatment of carcinoid syndrome - Google Patents

Uses of a somatostatin modulator for the treatment of carcinoid syndrome

Info

Publication number
IL314054A
IL314054A IL314054A IL31405424A IL314054A IL 314054 A IL314054 A IL 314054A IL 314054 A IL314054 A IL 314054A IL 31405424 A IL31405424 A IL 31405424A IL 314054 A IL314054 A IL 314054A
Authority
IL
Israel
Prior art keywords
day
compound
carcinoid syndrome
monohydrochloride
human
Prior art date
Application number
IL314054A
Other languages
English (en)
Hebrew (he)
Original Assignee
Crinetics Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Crinetics Pharmaceuticals Inc filed Critical Crinetics Pharmaceuticals Inc
Publication of IL314054A publication Critical patent/IL314054A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
IL314054A 2022-01-11 2023-01-10 Uses of a somatostatin modulator for the treatment of carcinoid syndrome IL314054A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263298551P 2022-01-11 2022-01-11
PCT/US2023/010493 WO2023137018A1 (en) 2022-01-11 2023-01-10 Uses of a somatostatin modulator for the treatment of carcinoid syndrome

Publications (1)

Publication Number Publication Date
IL314054A true IL314054A (en) 2024-09-01

Family

ID=87279605

Family Applications (1)

Application Number Title Priority Date Filing Date
IL314054A IL314054A (en) 2022-01-11 2023-01-10 Uses of a somatostatin modulator for the treatment of carcinoid syndrome

Country Status (11)

Country Link
US (1) US20250228842A1 (enExample)
EP (1) EP4463159A4 (enExample)
JP (1) JP2025501922A (enExample)
KR (1) KR20240132451A (enExample)
CN (1) CN118510511A (enExample)
AU (1) AU2023207068A1 (enExample)
CA (1) CA3242165A1 (enExample)
IL (1) IL314054A (enExample)
MX (1) MX2024008598A (enExample)
TW (1) TW202339747A (enExample)
WO (1) WO2023137018A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4482491A4 (en) * 2022-02-25 2026-02-25 Amryt Endo Inc ORAL OCTREOTIDE FOR THE TREATMENT OF A DISEASE

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
AU2017296392B2 (en) * 2016-07-14 2020-09-24 Crinetics Pharmaceuticals, Inc. Somatostatin modulators and uses thereof
MA51625B1 (fr) * 2018-01-17 2022-07-29 Crinetics Pharmaceuticals Inc Procédé de production de modulateurs de somatostatine
US12617767B2 (en) * 2019-07-17 2026-05-05 Crinetics Pharmaceuticals, Inc. Crystalline forms of somatostatin modulators
WO2022055880A1 (en) * 2020-09-09 2022-03-17 Crinetics Pharmaceuticals, Inc. Formulations of a somatostatin modulator

Also Published As

Publication number Publication date
CA3242165A1 (en) 2023-07-20
US20250228842A1 (en) 2025-07-17
JP2025501922A (ja) 2025-01-24
WO2023137018A1 (en) 2023-07-20
AU2023207068A1 (en) 2024-07-11
EP4463159A1 (en) 2024-11-20
TW202339747A (zh) 2023-10-16
EP4463159A4 (en) 2026-01-14
KR20240132451A (ko) 2024-09-03
CN118510511A (zh) 2024-08-16
MX2024008598A (es) 2024-07-23

Similar Documents

Publication Publication Date Title
Sachs et al. Novel approaches to inhibition of gastric acid secretion
Huang et al. Pharmacological and pharmacodynamic essentials of H2-receptor antagonists and proton pump inhibitors for the practising physician
Wallace et al. Pharmacotherapy of gastric acidity, peptic ulcers and gastroesophageal reflux disease
Robinson et al. Effects of oral rabeprazole on oesophageal and gastric pH in patients with gastro‐oesophageal reflux disease
US20070276007A1 (en) Administration of pharmaceuticals
JP2009511450A5 (enExample)
JPH04230330A (ja) 非ステロイド系抗炎症薬によつて起こる胃腸症候の緩和のための薬剤配合物と緩和法
KR20050090375A (ko) 테나토프라졸 및 항염증제를 배합한 약학 조성물
US20060234946A1 (en) Use of telmisartan for the prevention and treatment of vascular headache
AU1184097A (en) Use of certain angiotensin II type I receptor antagonists for dyspeptic symptons in mammals including man
RU2013112890A (ru) Терапевтическое применение 1-[2-(2,4-диметилфенилсульфанил)фенил]пиперазина
JP2022058873A5 (enExample)
Earnest et al. Treatment advances in acid secretory disorders: the promise of rapid symptom relief with disease resolution
Ricciardi et al. Adverse reactions to pantoprazole
US8058296B2 (en) Treatment and prevention of deleterious effects associated with alcohol consumption
JP2003516309A (ja) 涙液分泌障害を除く外分泌障害処置剤
CN1744896B (zh) 结合有泰妥拉唑和组胺h2受体拮抗剂的药物组合物
Keithley Histamine H2-receptor antagonists
US20170035757A1 (en) Method of Optimizing the treatment of Proliferative Diseases Mediated by the Tyrosine Kinase Receptor KIT with Imatinib
Onodera et al. Unique Profile of Lafutidine, A Novel Histamine H2-Receptor Antagonist-Mucosal Protection Throughout Gastrointestinal Tract Mediated by Capsaicin-Sensitive Afferent Neurons
AU2013201993B2 (en) Method of optimizing the treatment of proliferative diseases mediated by the tyrosine kinase receptor KIT with imatinib
Schentag et al. Pharmacokinetics and pharmacodynamics of acid-suppressive agents in patients with gastroesophageal reflux disease
US9457011B2 (en) Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor
US20190117669A1 (en) Methods for Treating NSAID-Induced Cardiovascular, Cerebrovascular, or Renovascular Adverse Events
RU2021137698A (ru) Применение 3-метил-7-[4-(бензгидрил-4-пиперазинил-1) бутил]ксантина и его солей для лечения орви